A cost analysis of COVID-19 vaccination: a comparison between mRNA-based and inactivated virus vaccines
Introduction: COVID-19 vaccination is considered a primary preventive measure to combat the COVID-19 pandemic. Several types of COVID-19 vaccines were developed, among them the mRNA-based vaccine and the inactivated virus vaccine. Different COVID-19 vaccines have different purchase price and require...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universiti Putra Malaysia Press
2024
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/112190/1/2024032615323329_MJMHS_0666.pdf http://psasir.upm.edu.my/id/eprint/112190/ https://medic.upm.edu.my/upload/dokumen/2024032615323329_MJMHS_0666.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: COVID-19 vaccination is considered a primary preventive measure to combat the COVID-19 pandemic. Several types of COVID-19 vaccines were developed, among them the mRNA-based vaccine and the inactivated virus vaccine. Different COVID-19 vaccines have different purchase price and require different logistics
system, which translate into different estimated vaccination costs. Therefore, this study aims to estimate the cost of
COVID-19 vaccination using the mRNA-based vaccine compared to the inactivated virus vaccine to assist future
decision-making related to COVID-19 vaccination. Methods: Direct costs for per-dose vaccination for both vaccines
were estimated from the health provider’s perspective using the microcosting approach. Vaccination pathways were
constructed for both the mRNA-based and the inactivated virus vaccine based on activities involving the acquisition,
transportation, storage, and vaccine injection processes. Cost value was obtained from purchase documents, asset
records, and market surveys. Results: The estimated costs for COVID-19 vaccination were RM 69.71 per dose for the
mRNA-based vaccine and RM 91.68 per dose for the inactivated virus vaccine. The difference in estimated vaccination costs was mainly driven by the difference in the vaccine purchase costs which was higher for the inactivated virus vaccine. Conclusion: COVID-19 vaccination using the mRNA-based vaccine incur was estimated to incur lower
total costs to the health provider compared to the inactivated virus vaccine during the pandemic. |
|---|